Has Stephan Busque, MD received payments from drug or device companies?

Yes. Drug and device makers reported $106,653 in general payments to Stephan Busque, MD across 9 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephan Busque, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephan Busque, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephan Busque, MD

Surgery · Stanford, CANPI 1508891052

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $106,130 of the $106,653 with a category attached, or 99.5%. Grifols, S.A. accounts for 92.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $98,186 and has fallen 99.7% since, to $319 in 2025. Among surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$106,653in general payments, 2019–2025

Across 9 payments — averaging $11,850 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Grifols, S.A.$98K
Genentech, Inc.$8K
Paragonix Technologies, Inc.$195
Johnson & Johnson$167
AstraZeneca$150
Intuitive Surgical$12

$20,110in research payments, 2019–2025

Across 5 payments — averaging $4021.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Roche Products Limited$20K

What the payments were for

Consulting fees$106,130100%
Speaking & faculty fees$1500%
Food & beverage$3610%
Gifts$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Grifols, S.A.	1	$98,186
Genentech, Inc.	2	$7,944
Paragonix Technologies, Inc.	2	$195
Johnson & Johnson	2	$167
AstraZeneca	1	$150
Intuitive Surgical	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SOLIRIS$150
KidneyVault$138
SURGICEL NU-KNIT$125
VISTASEAL$125
STRATAFIX$125
Echelon Flex$125
Harmonic$125

How this compares

$106,653 in reported general payments places this provider in the 95th percentile of 2,363 surgery providers in California.

See all surgery providers in California →

Medicare billing

Part B allowed, 2024

$127,520

Medicare patients

Services billed

335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VemlidyTenofovir Alafenamide	11	$14,024
EliquisApixaban	16	$10,779
CreonLipase/Protease/Amylase	11	$8,782
Valganciclovir Hcl	123	$7,247
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	17	$4,574
Insulin Lispro Kwikpen U-100Insulin Lispro	22	$3,193
Comfort Ez Pen NeedlePen Needle, Diabetic	29	$2,741
Mycophenolate Mofetil	33	$2,696
Humalog Kwikpen U-100Insulin Lispro	17	$2,469
Entecavir	22	$2,237
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic	32	$1,941
Novolog FlexpenInsulin Aspart	13	$1,749
Insulin Aspart FlexpenInsulin Aspart	12	$1,504
Nystatin	39	$942
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	11	$929

Paid to pharmacies, not to this prescriber.

Other surgery in Stanford

Timothy ChuterSan Francisco$8.8M
Santiago HorganSan Diego$2.8M
Rock LiuHayward$1.6M
David LouriePasadena$1.4M
Andrea PakulaThousand Oaks$1.4M
Siew-Ming LeeFresno$1.3M
Beemen KhalilPalo Alto$1.1M
John LiphamLos Angeles$942K
Alexander NedopilLodi$682K
Barry GardinerSan Ramon$602K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →